• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The American Journal of Tropical Medicine and Hygiene >Comparison of different artemisinin-based combinations for the treatment of Plasmodium falciparum malaria in children in Kigali, Rwanda, an area of resistance to sulfadoxine-pyrimethamine: artesunate plus sulfadoxine/pyrimethamine versus artesunate p
【24h】

Comparison of different artemisinin-based combinations for the treatment of Plasmodium falciparum malaria in children in Kigali, Rwanda, an area of resistance to sulfadoxine-pyrimethamine: artesunate plus sulfadoxine/pyrimethamine versus artesunate p

机译：卢旺达基加利不同地区以青蒿素为基础的组合药物治疗儿童恶性疟原虫疟疾的比较，卢卡达是对磺胺多辛-乙胺嘧啶有抗药性的地区：青蒿琥酯加磺胺多辛/乙胺嘧啶与青蒿琥酯p

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In view of the changing policy towards artemisinin-based combination therapies (ACTs), the efficacy, tolerance, and degree of re-infection of two ACTs were investigated: artesunate plus sulfadoxine/pyrimethamine (As + SP) and AS plus sulfamethoxypyrazine/pyrimethamine (As + SMP). One hundred three children were assigned to receive As + SP and 109 to receive As + SMP. In spite of the high incidence of resistance to SP, As + SP showed satisfactory results consistent with recent recommendations for ACTs (adequate clinical and parasitologic response on day 28 [ACPR] > or = 90%), but results with As + SMP fulfilled the most stringent criteria (ACPR > or = 95%). The absence of side effects and the low price of these drugs make them it worth to reconsider national therapies in favor of either of these two drug combinations.
机译：鉴于青蒿素为基础的联合疗法（ACT）政策的变化，研究了两种ACT的功效，耐受性和再感染程度：青蒿琥酯加磺胺多辛/乙胺（AS + SP）和AS加磺胺甲氧吡嗪/乙胺（ As + SMP）。分配了一百零三名儿童接受As + SP，109名儿童接受了As + SMP。尽管对SP耐药的发生率很高，但As + SP仍显示出令人满意的结果，与近期针对ACT的建议一致（在第28天[ACPR]>或= 90％时有足够的临床和寄生虫学反应），但As + SMP的结果令人满意最严格的标准（ACPR>或= 95％）。这些药物无副作用且价格低廉，因此有必要重新考虑国家疗法，以支持这两种药物中的任何一种。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号